Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001599298-23-000028)

Filing Details

Accession Number:: 0001599298-23-000028
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-03-08 21:31:10
Reporting Period:: 2023-03-08

Accepted Time:: 2023-03-08 21:31:10
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1599298	Summit Therapeutics Inc.	SMMT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1507650	Mahkam Zanganeh	C/O Summit Therapeutics Inc. 2882 Sand Hill Road, Suite 106 Menlo Park CA 94025	Co-Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-03-08	15,973,743	$1.05	23,395,269	No	4	P	Direct
Common Stock	Acquisiton	2023-03-08	804,672	$1.05	1,178,529	No	4	P	Indirect	By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee.
Common Stock	Acquisiton	2023-03-08	6,748,629	$1.05	9,884,095	No	4	P	Indirect	By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee.
No	4	P	Indirect	By the Shaun Zanganeh Irrevocable Trust, with the Reporting Person as Trustee.

Footnotes

Represents the number of shares of Common Stock that the Reporting Person purchased in the Issuer's rights offering.
The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.